Category Archives: Recent News

BriaCell Closes First Tranche of Previously Announced Non-Brokered Private Placement

BERKELEY, Calif., and VANCOUVER, British Columbia, March 25, 2019 — BriaCell Therapeutics Corp. (“BriaCell” or ...

BriaCell Announces $2,000,000 Non-Brokered Private Placement Offering

BERKELEY, Calif., and VANCOUVER, British Columbia, March 20, 2019 — BriaCell Therapeutics Corp. (“BriaCell” or ...

BriaCell Welcomes BioPharma Industry Experts to its Board of Directors

BERKELEY, Calif., and VANCOUVER, British Columbia, March 18, 2019 – BriaCell® Therapeutics Corp. (“BriaCell®” or ...

BriaCell Announces C$500,000 Equity Investment by BriaCell Director

BERKELEY, Calif., and VANCOUVER, British Columbia, February 26, 2019 — BriaCell Therapeutics Corp. (“BriaCell” or ...

BriaCell to Present Clinical and Scientific Findings with New Insights at Key Oncology Conferences

· New insights into BriaDX™, BriaCell’s simple patient HLA-type identification test, will be presented at ...

BriaCell Appoints Jamieson Bondarenko to its Board of Directors

BERKELEY, Calif., and VANCOUVER, British Columbia, February 12, 2019 – BriaCell Therapeutics Corp. (TSX-V:BCT) (OTCQB:BCTXF) ...

BriaCell Announces Switch to Novel Frozen Formulation for Lead Cancer Drug Candidate, Upcoming Attendance at Biotech Showcase™ 2019 and Presentation at Keystone Symposia Conference

· Completed development of a novel frozen formulation of Bria-IMT™ for on-demand shipment to clinical ...

BriaCell Presents Positive Efficacy Data with Lead Cancer Drug Candidate in Phase IIa Monotherapy and Excellent Initial Safety Data in Combination with KEYTRUDA® at a Major Breast Cancer Conference

· Interim data indicate an excellent safety profile for the combination regimen in advanced breast ...

UPDATED – BriaCell to Present Updated Clinical Data Including Early Safety Data in KEYTRUDA® Combination Study and Positive Phase IIa Monotherapy Efficacy Data at 2018 San Antonio Breast Cancer Symposium

Note: This Press Release contains amendments to the press release previously issued on Nov. 19, ...

BriaCell to Present Updated Clinical Data Including Early Safety Data in KEYTRUDA® Combination Study and Positive Phase IIa Monotherapy Efficacy Data at 2018 San Antonio Breast Cancer Symposium

· Positive proof of concept data with Bria-IMT™ Monotherapy will highlight potent anti-tumor activity and ...